Skip to Content
Merck
All Photos(1)

Key Documents

PZ0257

Sigma-Aldrich

WAY-252623

≥98% (HPLC)

Synonym(s):

2-[(2-Chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole, 2-[(2-Chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)indazole, CID 16734800, LXR-623, LXR623

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H12ClF5N2
CAS Number:
875787-07-8
Molecular Weight:
422.78
UNSPSC Code:
41121800
NACRES:
NA.77
Pricing and availability is not currently available.

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

room temp

SMILES string

FC(F)(F)c1c2n[n](c(c2ccc1)c4ccc(cc4)F)Cc3c(cc(cc3)F)Cl

InChI

1S/C21H12ClF5N2/c22-18-10-15(24)9-6-13(18)11-29-20(12-4-7-14(23)8-5-12)16-2-1-3-17(19(16)28-29)21(25,26)27/h1-10H,11H2

InChI key

KYWWJENKIMRJBI-UHFFFAOYSA-N

Biochem/physiol Actions

WAY-252623 (LXR623) is an orally available, potent and highly selective Liver X receptors (LXRs) agonist that significantly reduced total and LDL-cholesterol. WAY-252623 reduces lesion progression in the murine LDLR(-/-) atherosclerosis model.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
124M4719V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Weijun Wan et al.
Cell death & disease, 10(3), 248-248 (2019-03-15)
LXR-623 (WAY-252623), a liver X receptor agonist, reduces atherosclerotic plaque progression and remarkably inhibits the proliferation of glioblastoma cells, owing to its brain-penetrant ability. However, the role of LXR-623 against the proliferation of other cancer cells and the underlying mechanism
Chiara Giannarelli et al.
European heart journal, 33(2), 264-273 (2011-05-25)
The aim of this study was to investigate the effects of liver X receptors (LXRs)-β preferential activation by LXR-623 (WAY-252623), a novel LXRs agonist, on plaque progression/regression in a rabbit model of advanced atherosclerosis. Advanced atherosclerosis was induced in New
Chiara Giannarelli et al.
European heart journal, 33(2), 264-273 (2011-05-25)
The aim of this study was to investigate the effects of liver X receptors (LXRs)-β preferential activation by LXR-623 (WAY-252623), a novel LXRs agonist, on plaque progression/regression in a rabbit model of advanced atherosclerosis. Advanced atherosclerosis was induced in New

Articles

Discover Bioactive Small Molecules for Lipid Signaling Research

Discover Bioactive Small Molecules for Lipid Signaling Research

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service